Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
JARI Pharmaceutical
Lianyungang, Jiangsu, China
- Ownership
- Private
- Employees
- ~200
- Development stage
- Other
01
Overview
JARI Pharmaceutical has a diversified generics and APIs business, including an open, multicenter phase IV clinical trial for decitabine injection (a DNA methyltransferase inhibitor) for myelodysplastic syndrome (MDS). The study aimed to optimize dosing regimens, though it has been suspended[5]. The company primarily manufactures APIs and finished formulations for oncology and other indications[1][5][6].
- Therapeutic areas
- Oncology
- Modalities
- Small molecule
- Industry
- Biotech
Beyond the preview
Go deeper on JARI Pharmaceutical.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on JARI Pharmaceutical.